Key Takeaways
- Demerger unlocks value: The Board approved separating CHC into a new listed entity, a move management argues will let the consumer business be valued at its own higher multiples rather than pharma multiples.
- Record profitability delivered: Q1 delivered one of the highest profit quarters in 17–20 periods, with EBITDA margins reaching 31%, driven by growth and the India-for-India restructuring efficiencies.
- India-for-India strategy gaining traction: The restructuring from eight business units to three is complete, and early signs of success are visible in both the pharma and consumer businesses, with growth well distributed across units.
- CHC margin premium disclosed: Management committed that CHC margins will always be 8% to 10% higher than blended margins, and that operating profit percentage to sales will remain constant even through NLEM price impacts.
- What to watch next quarter: The pace of innovation launches (Soliqua now approved), any inorganic moves in CHC, and whether the portion of Q1 margin driven by lower promotional activity normalizes.
The Demerger: Two Listed Entities
- Structure approved: The Board approved demerging the consumer healthcare business into Sanofi Consumer Healthcare India Limited; shareholders receive one CHC share for every one Sanofi India share held, and Sanofi will hold 60.4% in both resulting entities.
- Timeline: Expected closure is mid-2024, subject to shareholder and regulatory approvals.
- Manufacturing split: The Goa manufacturing unit stays with the general medicines business, which will become a contract manufacturing organization for CHC, since CHC already sources some supply from Goa.
- Global context: This follows a path already taken globally by Haleon, Johnson & Johnson (Kenvue), and local peers; Sanofi’s global Project Chloe has been giving CHC autonomy within the group since January 2020.
- Rationale: Management sees the demerger as removing intertwined processes, giving each segment specific capabilities, and aligning them with respective global structures, which it believes will unlock significant shareholder value.
Hrosz: "We think that we can maximize the Sanofi India's potential and our current India for India plans potential by giving each of these segments specific capabilities, removing unnecessary and intertwined processes that today exist and fully aligning these businesses with the respective global structures."
India-for-India Strategy & Restructuring
- Five growth pillars: Launched in Q3 2022, the strategy focuses on diabetes, consumer healthcare, innovation, new go-to-market approaches, and partnerships.
- Organizational simplification: The company moved from eight business units to three, concentrating more resources on fewer bets where it believes it has a right to win; the significant organizational shift was absorbed within two quarters.
- Customer-centric redesign: The organization shifted from product-centric to patient- and HCP-centric, creating categories that cater more fully to HCPs dealing with a specific disease; diabetes, previously split across two business units, now sits under one larger portfolio.
- Trade organization launched: A new trade organization engages partners on a full-portfolio basis rather than brand-by-brand, unlocking opportunities.
- Digital route in development: COVID-era remote engagement capability is being repurposed into a digital route to reach HCPs and customers, though post-COVID adherence to that mode has declined and the model still needs more development.
- Innovation not yet contributing: The innovation process is longer in pharma; management expects it to impact positively in years to come but it has not been a factor in Q4 or Q1 so far.
CHC Business: Ambition & Economics
- Market opportunity: Management cited a global consumer healthcare market estimated at $158 billion, projected to exceed $200 billion by 2027, with multiple factors making growth sustainable for a very long time.
- India’s position: India ranks number six for consumer healthcare globally; for Sanofi, it already ranks number 10, and management sees the gap as an opportunity.
- Growth ambition: CHC aims to achieve growth twice as big as the category globally, with India playing a major role.
- Margin commitment: CHC margins will always be 8% to 10% higher than blended margins, and operating profit percentage to sales will remain constant even through NLEM price impacts, with purchase prices adjusted accordingly.
- Inorganic potential: Management confirmed potential for inorganic growth exists and will be looked at in the consumer healthcare segment; direct-to-consumer opportunities can also be explored down the road.
- Regulatory catalyst: Modern OTC regulation needs to be modernized; as it does, management believes it allows tremendous expansion.
Hrosz: "India is a very important key market for consumer healthcare in general. It is number six. It ranks number six for consumer healthcare globally. For Sanofi, it ranks already number 10. Even if you see already a gap there, even 10 is already very relevant."
General Medicines: Focus Areas
- Strategic priorities: Strengthen therapeutic areas, elevate disease awareness, improve scientific support and HCP engagement, accelerate innovation from the global portfolio and local opportunities, further localize manufacturing for gross margin expansion, and improve supply reliability and speed to market.
- Go-to-market evolution: Improve patient and customer centricity, accelerate digital transformation, and evaluate strategic partnerships to expand reach in competitive and resource-intensive therapeutic areas.
- Diabetes opportunity: Despite high prevalence, diagnosis rates are low; of those diagnosed, the percentage under treatment is not sufficiently good; and of those under treatment, there is a further step down to those treated and controlled, creating a large funnel of opportunity.
- Innovation pipeline: Soliqua, a global diabetes product, has been recently approved for launch in India; Sanofi globally also acquired Provention Bio, which developed Tzield, a breakthrough innovation that delays onset of type 1 diabetes by a number of years.
Margin Dynamics & Sustainability
- Record 31% EBITDA margin: Driven by two components: growth of the business, and India-for-India efficiencies from rationalizing operations significantly at the beginning of the year.
- What is sustainable: A portion of Q1 operating profit is permanent and continuing; another portion reflects lower promotional activities while teams were being restructured; restructuring costs were also part of those results, so the net effect is not all recurring.
- Operating expense efficiencies: The India-for-India strategy implementation, which started in 2022, continues to deliver better efficiencies in the operating structure.
- Working capital profile: Both GenMed and CHC have generally good working capital profiles; CHC is slightly better because most manufacturing is localized with a smaller imported component; both businesses are cash and carry.
- NLEM protection: Operating profit percentage to sales will remain constant despite NLEM price impact; purchase prices will be adjusted accordingly, though there might be a transitionary impact considering inventory levels.
Karandikar: "In the last investor call also we made the statement that the operating profit percentage to sales will remain constant. So it's not just gross margins, the operating profit percentage will remain constant. So we will adjust the purchase prices accordingly."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Demerger closure | Two listed entities: Sanofi India Ltd (GenMed) and Sanofi Consumer Healthcare India Ltd; 1:1 share swap; Sanofi holds 60.4% in both | Mid-2024, subject to approvals |
| CHC margin premium | CHC margins always 8% to 10% higher than blended margins | Ongoing |
| Operating profit protection | Operating profit percentage to sales remains constant through NLEM price impacts, via purchase price adjustments | Ongoing; transitionary inventory impact possible |
| Dividend payout | Maintain payout ratios going forward under India-for-India strategy | Ongoing |
| Renewable energy | 100% renewable energy | By 2030 |
| Net zero | Carbon net zero | By 2045 |
Key Metrics
| Metric | Q1 CY23 (Q4 FY23) |
|---|---|
| Revenue | ₹2,620 cr in CY22; Q1 CY23 comparable sales growth of 9% YoY |
| Operating profit growth | 21% YoY in Q1 CY23 |
| Operating profit growth (QoQ) | 40% vs Q4 CY22 |
| EBITDA margin | 31%, a record quarter |
| Consolidated operating profit margin | 25%–26% range |
| Profit before tax growth (Q4 CY22) | 22% YoY |
| Dividend payout ratio | 85% (last payout) |
| Dividend yield | ~3%–3.5% |
| Consumer healthcare revenue share | ~28% of total business, turnover of ~₹700 cr annually |
| Consumer healthcare historical growth | ~8%–8.5% CAGR from 2018 onwards |
| Consumer healthcare margin premium | 8%–10% higher than blended consolidated margins |
| Diabetes sales force | ~2x resources deployed vs prior |
| NLEM price impact timing | Not in Q1 CY23; Lantus impact from April (Q2 CY23) onwards |
| Total shareholder returns (2010–2023) | 5x, CAGR of 12.2% |